At meeting held on 26 July 2019
The Board of Max Ventures and Industries at its meeting held on 26 July 2019 has approved further investment / loan in Max Estates ("MEL"), a wholly owned subsidiary of the Company.MEL shall utilize the aforesaid funds for acquisition of ~85.17% equity share capital of Pharmax Corporation ("Pharmax"), from Max India, another Max Group Company ("Proposed Transaction") for an aggregate consideration of Rs. 61.2 crore (on the basis of the valuation report of an independent valuer), subject to closing adjustments and other terms and conditions of the Share Purchase Agreement ("SPA") to be executed amongst MEL, Max India and Pharmax (collectively referred as "Parties") and receipt of requisite approvals. Consequent to the completion of the acquisition, Pharmax shall become a step down subsidiary of the Company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
